Teva Pharmaceutical Industries Ltd

Teva insider buying signals confidence in its biologics pivot, reflecting a strategic shift toward higher‑margin drugs amid Blackstone partnership.

Teva’s insider buying—chiefly by accounting officer Weiss Amir—signals executive confidence amid a $400 M Blackstone partnership, despite negative sentiment.

Teva CEO’s February 2026 trades show a measured buy‑sell balance—boosting his stake while liquidating restricted units—indicating confidence, not distress.

Teva insiders boost confidence with restricted‑unit purchases, signaling long‑term stake and bullish outlook for branded drug growth.